Pfizer discontinued its final Trillium Therapeutics program while topping Wall Street estimates on the strength of newer products. In clinical data, Cytokinetics' Myqorzo met twin endpoints in genetic heart disease while Viridian's thyroid eye disease candidate delivered results analysts viewed as competitive with Amgen's Tepezza. Meanwhile, Madrigal struck a $1B deal with Arrowhead for a siRNA MASH asset to potentially complement its lead therapy Rezdiffra.
Top Stories
Cytokinetics' Myqorzo Hits Dual Primary Endpoints in Genetic Heart Disease Trial
Cytokinetics' heart disease drug Myqorzo (aficamten), already approved for obstructive HCM, succeeded in meeting twin efficacy goals in its pivotal Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy, the company announced and STAT reported. The positive readout in this genetic heart condition represents a potential expansion opportunity that could boost commercial prospects beyond the drug's current label. This signals growing confidence in cardiac myosin inhibitors as a platform approach across multiple cardiomyopathy subtypes.
Viridian's Thyroid Eye Disease Drug Shows Competitive Profile in Chronic Patient Population
Viridian's elegrobart delivered Phase 3 results in chronic thyroid eye disease that BioPharma Dive notes were viewed by analysts as much more competitive with Amgen's Tepezza than earlier data in the acute setting, which had disappointed Wall Street. Endpoints News also highlighted the win among its daily roundup. The differentiated performance in chronic disease suggests elegrobart may carve out a distinct patient segment where Tepezza has shown limitations.
J&J Advances IBD Combo to Phase 3 Despite Mid-Stage Failures
Johnson & Johnson will move JNJ-4804, a combination of blockbuster drug Tremfya with an undisclosed second agent, into Phase 3 testing for inflammatory bowel disease despite the therapy failing to meet endpoints in two Phase 2 studies, according to Endpoints News. The decision to advance despite setbacks suggests J&J sees sufficient signal in secondary endpoints or subgroups to justify pivotal investment. Worth watching whether the company has redesigned trial parameters or identified a more responsive patient population for the Phase 3 program.
Madrigal Pays $1B Upfront for Arrowhead's siRNA MASH Asset
Pharmaceutical Technology reports that Madrigal Pharmaceuticals has outlaid $1 billion to acquire Arrowhead's siRNA candidate targeting metabolic dysfunction-associated steatohepatitis (MASH). As with a previous siRNA deal, Madrigal plans to explore whether gene-silencing technology could complement its lead drug Rezdiffra, which recently gained approval. The move signals Madrigal's intent to build a multi-mechanism franchise in MASH rather than relying solely on a single-asset strategy.
Pfizer Beats Estimates as R&D Spend Jumps, Discontinues Final Trillium Program
Pfizer topped Wall Street estimates for Q1 2026, reaffirming its full-year outlook as newer products offset declining Covid revenues. Concurrently, Endpoints News notes the company discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, redirecting capital primarily toward oncology and obesity programs. The Trillium wind-down underscores Pfizer's ongoing portfolio rationalization as it pivots away from deals that haven't delivered anticipated clinical traction.
MimiVax Opens Phase 2 Trial of SurVaxM in Metastatic Neuroendocrine Tumors
MimiVax and Roswell Park have initiated a Phase 2 trial evaluating SurVaxM, a survivin-targeting vaccine, in patients with metastatic neuroendocrine tumors, PharmaTimes reports. The study expands evaluation of the vaccine platform beyond its prior focus areas. This signals continued exploration of tumor-associated antigen vaccines in rare oncology indications where treatment options remain limited.
What to Watch
- Myqorzo Label Expansion Timeline — Cytokinetics will likely file for regulatory approval in non-obstructive hypertrophic cardiomyopathy by Q3 2026, potentially doubling the addressable patient population for the already-approved therapy.
- J&J's Phase 3 IBD Design — The decision to advance JNJ-4804 despite Phase 2 failures suggests either protocol amendments or enriched patient selection criteria; pivotal trial design details will clarify the company's confidence level.
- Madrigal Combination Strategy — With $1B committed to Arrowhead's siRNA asset, watch for Phase 2 combination data with Rezdiffra that could establish multi-mechanism therapy as the MASH standard of care.
- Viridian Commercial Positioning — Following positive chronic thyroid eye disease data, pricing and payer strategy will determine whether elegrobart can gain meaningful share in a market dominated by Tepezza's first-mover advantage.
Market Snapshot
- Pfizer Portfolio Shift: The discontinuation of Trillium programs and redirection of R&D spend toward obesity and oncology reflects broader industry dynamics where large pharma are pruning underperforming assets to fund higher-conviction bets in crowded therapeutic areas.
- MASH Dealmaking Heats Up: Madrigal's $1B upfront payment for an siRNA asset underscores the premium buyers will pay for differentiated mechanisms in liver disease, particularly as first-generation therapies like Rezdiffra establish proof of concept.
- Rare Disease Vaccine Interest: The expansion of MimiVax's SurVaxM into metastatic neuroendocrine tumors highlights sustained investor and clinical interest in personalized cancer vaccines despite mixed results across the broader field.